Compare CABO & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABO | DMAC |
|---|---|---|
| Founded | 1980 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.5M | 347.5M |
| IPO Year | 2015 | 2018 |
| Metric | CABO | DMAC |
|---|---|---|
| Price | $50.94 | $6.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $125.67 | $15.50 |
| AVG Volume (30 Days) | ★ 197.4K | 141.6K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.12 | N/A |
| Revenue | ★ $1,501,423,000.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.83 | N/A |
| P/E Ratio | $9.20 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $45.37 | $3.48 |
| 52 Week High | $180.74 | $10.42 |
| Indicator | CABO | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 34.88 | 46.41 |
| Support Level | $45.37 | $5.76 |
| Resistance Level | $117.15 | $6.18 |
| Average True Range (ATR) | 4.67 | 0.32 |
| MACD | 1.66 | 0.03 |
| Stochastic Oscillator | 34.60 | 46.86 |
Cable One Inc is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. The company derives majority of its revenue from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.